Impact of Vancomycin Exposure on Outcomes in Patients With Methicillin-Resistant Staphylococcus aureus Bacteremia: Support for Consensus Guidelines Suggested Targets
The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
BACKGROUND: High rates of vancomycin failure in methicillin-resistant Staphylococcus aureus (MRSA) infections have been increasingly reported over time. The primary objective of our study was to determine the impact of vancomycin exposure and outcomes in patients with MRSA bacteremia initially treated with vancomycin. METHODS: This was a single-center retrospective analysis of 320 patients with documented MRSA bacteremia initially treated with vancomycin from January 2005 through April 2010. Two methods of susceptibility, Etest and broth microdilution, were performed for all isolates to determine the correlation of susceptibility testing to patient outcomes. RESULTS: Among a cohort of 320 patients, more than half (52.5%) experienced vancomycin failure. Independent predictors of vancomycin failure in logistic regression included infective endocarditis (adjusted odds ratio [AOR], 4.55; 95% confidence interval [CI], 2.26-9.15), nosocomial-acquired infection (AOR, 2.19; 95% CI, 1.21-3.97), initial vancomycin trough <15 mg/L (AOR, 2.00; 95% CI, 1.25-3.22), and vancomycin minimum inhibitory concentration (MIC) >1 mg/L by Etest (AOR, 1.52; 95% CI, 1.09-2.49). With use of Classification and Regression Tree (CART) analysis, patients with vancomycin area under the curve at 24 h (AUC(24h)) to MIC ratios <421 were found to have significantly higher rates of failure, compared with patients with AUC(24h) to MIC ratios >421 (61.2% vs 48.6%; P = .038). CONCLUSIONS: In light of the high failure rates associated with this antimicrobial, optimizing the pharmacokinetic/pharmacodynamic properties of vancomycin by targeting higher trough values of 15-20 mg/L and AUC(24h)/MIC ratios ≥400 in selected patients should be considered.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically
Ferraro, M. J. (2000) · Cited by 16,875
System, A. R. F. T. N. (2003) · American Journal of Infection Control · doi:10.1016/j.ajic.2003.09.002 · Cited by 2,915
Lina, G., Piemont, Y., Godail-Gamot, F., Bes, M., Peter, M.-O., Gauduchon, V., Vandenesch, F., & Etienne, J. (1999) · Clinical Infectious Diseases · doi:10.1086/313461 · Cited by 2,489 · cited 1×
“genes encoding Panton–Valentine leukocidin, and agr group and agr function were determined using previously described methods [24, 25].”
MethodSystem, A. R. F. T. N. (2004) · American Journal of Infection Control · doi:10.1016/j.ajic.2004.10.001 · Cited by 2,342
Federal Funding for the Study of Antimicrobial Resistance in Nosocomial Pathogens: No ESKAPE
Rice, L. B. (2008) · The Journal of Infectious Diseases · doi:10.1086/533452 · Cited by 2,310
Zhang, K., McClure, J.-A., Elsayed, S., Louie, T., & Conly, J. M. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.10.5026-5033.2005 · Cited by 1,037
Cosgrove, S. E., Qi, Y., Kaye, K. S., Harbarth, S., Karchmer, A. W., & Carmeli, Y. (2005) · Infection Control & Hospital Epidemiology · doi:10.1086/502522 · Cited by 856
Levine, D. P. (2006) · Clinical Infectious Diseases · doi:10.1086/491709 · Cited by 838
Self-citationSakoulas, G., Moise-Broder, P. A., Schentag, J., Forrest, A., Moellering, R. C., & Eliopoulos, G. M. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.6.2398-2402.2004 · Cited by 836
The emergence and evolution of methicillin-resistant Staphylococcus aureus
Hiramatsu, K., Cui, L., Kuroda, M., & Ito, T. (2001) · Trends in Microbiology · doi:10.1016/s0966-842x(01)02175-8 · Cited by 825
Cited by
Items 401–460 of 460
Hirano, R., Teshiromori, R., & TACHIBANA, N. (2014) · Japanese Journal of Infection Prevention and Control · doi:10.4058/jsei.29.117
Luiz, M. V. D. S. J. (2011) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.42.2011.tde-09022012-153405
Antibiotics in Treatment of Periprosthetic Joint Infections
Soriano, À. (2013) · Springer eBooks · doi:10.1007/978-1-4614-7928-4_9
Therapeutic Options for Resistant Gram Positives
Menon, V., & van Hal, S. J. (2014) · Current treatment options in infectious diseases/Current treatment options in infectious disease · doi:10.1007/s40506-014-0028-y
Implantation d’une nouvelle règle d’utilisation de la vancomycine : une étude pré–post
Lavoie, A., Delicourt, A., Penfornis, S., Lebel, D., Ovetchkine, P., & Bussières, J. (2013) · Le Pharmacien Hospitalier et Clinicien · doi:10.1016/j.phclin.2012.12.002
Monmaturapoj, T. (2015) · Srinagarind Medical Journal (SMJ) - ศรีนครินทร์เวชสาร
Shime, N. (2013) · Journal of the Japanese Society of Intensive Care Medicine · doi:10.3918/jsicm.20.561
Zuger, A. (2011) · Journal watch · doi:10.1056/jw201105170000001
Observation of ''Seesaw Effect'' with Vancomycin, Teicoplanin, Daptomycin and Ceftaroline in 150
Ireland, E., & Rybak, J. M. (2014)
Wilson, R. L., & Stayer, B. (2014) · Journal of Pharmacy and Pharmacology · doi:10.17265/2328-2150/2014.12.004
Antibiotic Stewardship and Applications of Pharmacodynamics
Hermsen, E. D., & Fehrenbacher, L. (2016) · Methods in pharmacology and toxicology · doi:10.1007/978-1-4939-3323-5_25
Vancomycin Pharmacodynamics: Optimal vs. Controversial
Lomaestro, B. M. (2016) · Methods in pharmacology and toxicology · doi:10.1007/978-1-4939-3323-5_11
A Case of Ventilator-Associated Pneumoniae Complicated with Antibiotics-induced Severe Drug Eruption
Matsunaga, N., Suda, S., Hatanaka, E., Ikeda, T., Ueno, T., & Okuyama, K. (2015) · Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) · doi:10.5649/jjphcs.41.651
Tennant, S. (2016) · UKnowledge (University of Kentucky) · doi:10.13023/etd.2016.298
Laboratory Tests to Direct Antimicrobial
Aeschlimann, R. (2014)
Advances in the Diagnosis and Treatment of Infective Endocarditis
Turner, R. B., & Schwartz, J. (2017) · Advances in medical diagnosis, treatment, and care (AMDTC) book series · doi:10.4018/978-1-5225-2092-4.ch010
Methicillin-Resistant Staphylococcus aureus: A Pharmacotherapy Primer
Molloy, L. M. (2017) · Journal of Pediatric Health Care · doi:10.1016/j.pedhc.2016.12.003 · Cited by 1
A Review of Vancomycin Population Pharmacokinetic Studies in Adult Critically Ill Patient
Setiawan, E., & Montakantikul, P. (2012) · ASEAN/Asian Academic Society International Conference (AASIC) Proceeding Series (Indonesian Student Association in Thailand (Permitha))
Appropriate Antimicrobial Therapy in Critically Ill Patients
Sime, F. B., & Roberts, J. A. (2017) · Hot topics in acute care surgery and trauma · doi:10.1007/978-3-319-59704-1_21
Sohn, K. (2013) · Journal of Korean Society of Health-System Pharmacists · doi:10.32429/jkshp.2013.30.3.002
Analysis of Vancomycin Plasma Concentrations Following Initial Dosing in Critically Ill Patients
임유진, 전수정, 박상헌, 이은숙, 송경호, 박가영, & 남궁형욱 (2014) · Journal of Korean Society of Health-System Pharmacists · doi:10.32429/jkshp.2014.31.4.002
Does AUC/MIC Ratio Predict Efficacy and Safety of Vancomycin?
Arasteh, O., & Khalili, H. (2019) · Avicenna Journal of Clinical Microbiology and Infection · doi:10.34172/ajcmi.2019.07
What Every Steward Should Know About Pharmacokinetics and Pharmacodynamics
Pogue, J. M., & Scheetz, M. H. (2018) · Cambridge University Press eBooks · doi:10.1017/9781316694411.009
El-Morsy, I. N. M., El-Asmar, A. B. H., & Ayoob, A. S. (2021) · Al-Azhar Medical Journal · doi:10.21608/amj.2021.158485
“Table (11) showed the demographic characteristics and medical history of the studied subgroups in which the average age of DM & Linezolid group was 63.”
BackgroundInfluentialMATSUKI, Y., Matsumoto, H., Sako, K.-I., YAJIMA, M., WATANABE, T., & Watanabe, S. (2020) · Japanese Journal of Infection Prevention and Control · doi:10.4058/jsei.35.223
Precision Drug Delivery for Vancomycin Efficacy and Safety in Critically Ill Patients
Flannery, A. H. (2021) · UKnowledge (University of Kentucky) · doi:10.13023/etd.2021.066
Editorial: Model-Based Evaluation of Antimicrobial Agents in Children
Zhao, W., Wu, Y., & van den Anker, J. N. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.731209
“The unwanted side effects or toxicity caused by supratherapeutic drug exposure and treatment failure caused by subtherapeutic drug exposure may occur (Imani et al., 2017; Kullar et al., 2011).”
BackgroundApplication of Vancomycin Therapeutic Drug Monitoring in a Vietnamese Private Hospital
Phương, N. T. T., Long, T. H., Anh, T. V., & Hoi, N. T. (2021) · World Congress on Medical Physics and Biomedical Engineering, September 7 - 12, 2009, Munich, Germany · doi:10.1007/978-3-030-75506-5_30
肝臓の解剖・生理,肝硬変の病態生理 (ナーシングプロセス 肝硬変患者の看護)
平川, 雅., & 佐藤, 譲. (2001) · クリニカルスタディ
Goutelle, S., & Guilhaumou, R. (2018) · Elsevier eBooks · doi:10.1016/b978-2-294-75300-8.00002-1
Vancomycin dosing in patients with obesity
Erstad, B. L., Matthias, K. R., & Nix, D. E. (2022) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxac229
Association Between Vancomycin AUC and Clinical Failure in Patients with Streptococcal Bacteremia
Aycock, A., Smith, J. M., Coe, K. E., Wang, S., & Reed, E. E. (2022) · Hospital Pharmacy · doi:10.1177/00185787221139424
Maung, N. H. (2020) · Chula Digiverse · doi:10.58837/chula.the.2020.117
Schneider, C. A., Rodriguez, W., Martinez, J., & Wolowich, W. R. (2023) · Advances in Infectious Diseases · doi:10.4236/aid.2023.133036 · Cited by 1
Kobayashi, Y., Nakagawa, T., Kawazu, T., Moriasa, N., Arakawa, M., & Karasuno, T. (2022) · Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) · doi:10.5649/jjphcs.48.562
Trương, T. Q., Huỳnh, P. T., Hà, M. P., Chau, V. N., Lê, T. M. V., Nguyễn, P. T. N., Nguyễn, V. V. C., & Nguyễn, T. H. Y. (2024) · Tạp chí Y học Việt Nam · doi:10.51298/vmj.v534i1b.8273
Prado, I. R. S., Vicentini, C. A. D. A., Cardoso, P. A., Carneiro, M. V., Chiarotti, A. D. M. M., de Souza, V. B., Ponce, D., & Zamoner, W. (2024) · Seven Editora eBooks · doi:10.56238/sevened2024.001-051
Presley, B. J., Halim, S. V., & Setiawan, E. (2024) · Journal of Applied Pharmaceutical Science · doi:10.7324/japs.2024.194102
Liu, X., Enoki, Y., Taguchi, K., & Matsumoto, K. (2024) · Journal of Pharmacy and Pharmacology · doi:10.1093/jpp/rgae124
Colorimetric quantification of vancomycin by highly active nitroxyl radical compounds
Sugiyama, K., Sato, F., Yoshida, K., Komatsu, S., Ono, T., Sasano, Y., Iwabuchi, Y., Fujimura, T., Kashiwagi, Y., & Sato, K. (2024) · Analytical Sciences · doi:10.1007/s44211-024-00686-5
Chenhsu, R.-Y., Hall, B. A., Tran, H., Donnelley, M., Cheema, R., & Nakra, N. A. (2025) · The Journal of Pediatric Pharmacology and Therapeutics · doi:10.5863/1551-6776-30.1.52
Kobayashi, Y., Kamano, K., Kawazu, T., Fukuma, H., Karasuno, T., & Fukatsu, S. (2025) · Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) · doi:10.5649/jjphcs.51.242
Amador, J. S., Vega, Á., Araos, P. A., Quiñones, L. A., & Amador, C. A. (2025) · Pharmaceuticals · doi:10.3390/ph18050677
“Moise-Broder et al. observed that AUC 0–24 /MIC values of ≥ 400 present successful outcomes in patients with S. aureus -associated pneumonia [10], while lower values are associated with a poor eradication of the infection, longer treatment duration, and high mortality rate [11].”
Staphylococcus aureus Infections (Coagulase-Positive Staphylococci)
Kaplan, S. L., & Hultén, K. G. (2025) · Elsevier eBooks · doi:10.1016/b978-0-323-82763-8.00080-7
Tsutsuura, M., Moriyama, H., Kojima, N., Mizukami, Y., Tashiro, S., Osa, S., Enoki, Y., Taguchi, K., Oda, K., Fujii, S., et al. (2021) · Figshare · doi:10.6084/m9.figshare.13727492
Tsutsuura, M., Moriyama, H., Kojima, N., Mizukami, Y., Tashiro, S., Osa, S., Enoki, Y., Taguchi, K., Oda, K., Fujii, S., et al. (2021) · Figshare · doi:10.6084/m9.figshare.13727489
Bondareva, I. B., Zyryanov, S. K., Asetskaya, I. L., Станиславович, Ч. М., & Gorbacheva, A. A. (2025) · Antibiot Khimioter = Antibiotics and Chemotherapy · doi:10.37489/0235-2990-2025-70-9-10-77-90
Wang, J., Huang, C., Chen, Y., Huang, Y., & Wu, Z. (2026) · Scientific Reports · doi:10.1038/s41598-026-42395-1
“Multiple studies have shown that higher doses significantly increase nephrotoxicity risk, with rates reaching 12–42.7% 10,11,36,62,63 .”
InfluentialCold atmospheric plasma stimulates macrophage killing of bacterial pathogens
Blaise, O. (2022) · theses.fr (ABES) · doi:10.70675/8f17afdcz03f2z4d56z8f89z76eb15533502
Alzeer, H. S., Alsufyani, A. T., Alwathnani, M. S., Althobaiti, A., Almusa, M. A., Alamri, F. M., Aldossari, H. H., Alshehri, Y. M., Mukhtar, L. E., Alreshoodi, F. M., et al. (2026) · Antibiotics · doi:10.3390/antibiotics15050470
Sujjavorakul, K., Kerr, S. J., Wacharachaisurapol, N., Samransamruajkit, R., & Puthanakit, T. (2026) · Pediatric Research · doi:10.1038/s41390-026-05112-2
Zhu, H., Liao, J., Wu, W., Gu, F., Zhu, T., Huang, X., Zhang, J., & LiXia, L. I. (2026) · Microbiology Spectrum · doi:10.1128/spectrum.00937-26
Tang, J., Shen, D., Zhou, X., Xiao, L., Yuan, X., & Hu, B. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1817481
“…clinical dilemma: clinicians are making dose adjustments based on a metric (VTC) whose relationship with the desired outcome (efficacy) is weak and inconsistent (Hou et al., 2021), yet whose association with a major harm (nephrotoxicity) appears strong and dose-dependent (Kullar et al., 2011).”
Anh, T. V., Bui, T. T., Ngan, T. T., Long, N. D., Giang, N. H., Nguyen, H. A., Vu, D. H., Dung, H. V., & Phương, N. T. T. (2026) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.70265
Honoré, P. M., Benkaddour, Y., & Muscato, C. Y. (2026) · Critical Care · doi:10.1186/s13054-026-06267-4
“A significantly higher incidence of nephrotoxicity was observed only when trough concentrations exceeded 20 mg/L (27%, P = 0.032) [3].”
Influential
Metadata
- Authors
- Kullar, R., Davis, S. L., Levine, D. P., & Rybak, M. J.
- Affiliations
- Eugene Applebaum College of Pharmacy and Health Sciences (US)
- Wayne State University (US)
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-04-01
- Volume
- 52
- Issue
- 8
- Pages
- 975-981
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2099365065
- Semantic Scholar
- ed3c7f78a7e345dd4578c14051be67b5da32fd88
- Cited by
- 463
- References
- 44
- Citations by year
- 2026: 11 · 2025: 10 · 2024: 15 · 2023: 15 · 2022: 22 · 2021: 37 · 2020: 33 · 2019: 40 · 2018: 27 · 2017: 26 · 2016: 30 · 2015: 37 · 2014: 43 · 2013: 57 · 2012: 45
- FWCI
- 34.30
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Astellas Pharma
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Keywords
- vancomycin, methicillin-resistant Staphylococcus aureus, MRSA bacteremia, pharmacokinetic/pharmacodynamic targets, AUC/MIC ratio, trough concentration, infective endocarditis, nosocomial infections, antimicrobial susceptibility testing, E-test, broth microdilution
- MeSH terms
- Anti-Bacterial Agents, Humans, Microbial Sensitivity Tests, Middle Aged, Retrospective Studies, Staphylococcal Infections, Vancomycin, Bacteremia, Treatment Outcome, Guidelines as Topic, Methicillin-Resistant Staphylococcus aureus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.